Warfarin pharmacogenetics meets clinical use.

摘要

The FDA in their revised approval of the warfarin prescribing information of 2007 noted the relevance of genetic testing for VK0RC1 and CYP2C9 variants. Yet there is still a lack of prospective clinical trials using genetic testing, underscoring the difficulty of a pharmacogenetics-based initiation dosing strategy. In this issue of Blood, Gong and colleagues provide evidence for the clinical use of a newly established warfarin pharmacogeneties-initiation protocol (WRAPID).